# C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/CCCC/c4-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-70d8c55a
Ticker: CCCC
Company: C4 Therapeutics
Source: C4 Therapeutics
Published: 2026-05-18 20:01 EST
## Summary

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...

## Article Body
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on May 18, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee’s start date, with the remainder of the shares vesting in thirty-six equal monthly installments thereafter, subject to the employee’s continued employment with C4T through each vesting date.

About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO ® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com .

Contacts: Investors: Courtney Solberg Associate Director, Investor Relations CSolberg@c4therapeutics.com

Leah Gibson Vice President, Investor Relations & Communications LGibson@c4therapeutics.com

Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy LSpreen@c4therapeutics.com
## Recent Company News
- 2026-06-11 11:00 EST — [C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population](https://biopharmsignal.com/news/CCCC/c4-therapeutics-presents-phase-1-data-at-european-hematology-association-eha-202-2551b658) — Source: C4 Therapeutics
- 2026-05-20 11:00 EST — [C4 Therapeutics to Participate in Upcoming Conferences](https://biopharmsignal.com/news/CCCC/c4-therapeutics-to-participate-in-upcoming-conferences-10ae0b56) — Source: C4 Therapeutics
- 2026-05-18 20:01 EST — [C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/CCCC/c4-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-70d8c55a) — Source: C4 Therapeutics
- 2026-05-12 11:00 EST — [C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/CCCC/c4-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-dc6ffcc8) — Source: C4 Therapeutics
- 2026-04-09 10:59 EST — [C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)](https://biopharmsignal.com/news/CCCC/c4-therapeutics-expands-long-term-partnership-with-roche-through-new-collaborati-b523cd96) — Source: C4 Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)